Company Statements

Biocon Biologics  /  Company Statements

Biocon Malaysia Receives MHRA Approval for New Drug Product Fill Finish Unit for Insulins

  • Posted by: Biocon Biologics

Biocon Announces Pegfilgrastim Biosimilar Marketing Approval by Japan Ministry of Health, Labour and Welfare (MHLW)

  • Posted by: Biocon Biologics

Biocon Announces U.S. FDA Approval for Yesintek® (ustekinumab-kfce) Single-dose Prefilled Autoinjector

  • Posted by: Biocon Biologics

U.S. FDA Completes Pre-License Inspection at Biocon’s Biosimilars Site at Biocon Park, Bengaluru, India

  • Posted by: Biocon Biologics

Biocon Biologics’ Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)

  • Posted by: Biocon Biologics

U.S. FDA Completes Inspection at Biocon Biologics’ Facility at Biocon Campus, Bengaluru, India

  • Posted by: Biocon Biologics

Biocon Biologics Launches Nepexto®, a Biosimilar to Enbrel® (Etanercept), in Australia

  • Posted by: Biocon Biologics

Biocon Biologics Receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars

  • Posted by: Biocon Biologics

Biocon Biologics Receives MHRA, UK Approval for YESINTEK®, Biosimilar Ustekinumab

  • Posted by: Biocon Biologics

Malaysian MoH Awards Insulins Supply Contract Extension to Biocon Biologics

  • Posted by: Biocon Biologics